Tirzepatide Phase 2 obesity trials: what the early evidence showed

Step 1: what phase 2 trials are actually testing

Clinical drug development runs in numbered phases. Phase 1 focuses on safety in small healthy-volunteer groups. Phase 3 is the large randomised controlled trial that supports a licence application. Phase 2 sits in between, it's the dose-finding and proof-of-concept stage, typically in several hundred participants rather than thousands.

For tirzepatide in obesity, the key phase 2 study randomised adults with type 2 diabetes and a BMI of at least 27 across multiple dose arms. Researchers were asking two questions: does this molecule reduce body weight at a clinically meaningful level, and which doses produce the best balance of efficacy and tolerability? Both questions needed answering before Eli Lilly could justify the cost and scale of the SURMOUNT phase 3 programme.

Results across the dose arms showed that weight loss climbed consistently with dose, with the 10mg and 15mg arms producing the largest reductions from baseline. That signal (dose-dependent and durable over 26–40 weeks) was the green light for the phase 3 SURMOUNT trials that eventually underpinned Mounjaro's UK licence.

Step 2: the dose-range lessons that reached UK prescribers

One of the most practically important outputs of phase 2 was the decision to start treatment at a sub-therapeutic dose. Participants in the lower dose arms reported fewer gastrointestinal events (nausea, loose stools, reduced appetite to the point of discomfort) than those assigned directly to 10mg or 15mg. That observation shaped the licensed titration ladder now used in the UK: 2.5mg for the first four weeks purely to settle the digestive system, followed by stepwise increases directed by the prescriber.

A question our prescribers hear most weeks is why the starter pen seems to do so little. The answer is in the phase 2 data: 2.5mg was never designed to produce substantial weight loss on its own. Its job is adjustment. The therapeutic work begins as doses climb.

The NHS patient information for tirzepatide reflects this directly, describing the escalation schedule and the rationale for taking time at each level before moving up.

Step 3: from phase 2 signal to NICE recommendation

Phase 2 data alone cannot get a medicine onto a clinical guideline. The route from those early findings to a NICE technology appraisal ran through SURMOUNT-1 and the wider phase 3 programme, which enrolled thousands of adults without diabetes and produced average weight reductions of around 20–21% at 15mg over 72 weeks, figures cited directly in NICE's appraisal of tirzepatide (TA1026), published December 2024.

NICE's recommendation covers adults with a BMI of at least 35 alongside at least one weight-related health condition, for NHS use. Private prescribing follows the licensed indication: BMI of 30 or above, or 27 and above with a relevant comorbidity. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Whether the phase 2 findings feel remote or recent, they represent the groundwork on which those current eligibility criteria sit.

If you want to understand where tirzepatide's evidence base now stands after the full development programme, the Mounjaro overview covers the clinical picture in full. For context on what private treatment costs and what that price covers, the cost context page sets out the landscape honestly.

Step 4: side effects identified in phase 2 and what changed by phase 3

The gastrointestinal adverse events flagged in phase 2 did not disappear in phase 3, they were confirmed and characterised more precisely. Nausea, vomiting, diarrhoea and constipation are the most commonly reported effects across the clinical programme. They tend to peak shortly after a dose increase and ease within a week or two for most people as the body adapts.

Phase 2 also identified a small number of participants with elevated pancreatic enzyme levels, which contributed to the prescribing caution around pancreatitis that appears in the current UK SmPC. The MHRA issued a Drug Safety Update in January 2026 confirming acute pancreatitis as an infrequent but serious known risk across GLP-1 medicines: seek urgent medical attention for severe, persistent stomach pain that spreads to the back. Suspected side effects from any medicine can be reported at the MHRA Yellow Card scheme.

On the liver side, phase 2 observations in participants with metabolic-associated conditions fed into the ongoing investigation of tirzepatide in NASH and related liver disease, a separate line of research tracked in the NASH phase 3 programme. That work is distinct from Mounjaro's current UK weight-management licence but illustrates how the molecule's early signal continues to expand.